Company expands management group with professional sector leaders as it improvements precision medicine pipeline for autoimmune diseases
CAMBRIDGE, Mass., April 14, 2022–(Business enterprise WIRE)–Rheos Medications, a biopharmaceutical company bringing molecular concentrating on and precision remedy to autoimmune and inflammatory conditions, these days declared the appointment of Katerina Leftheris, Ph.D., as Senior Vice President of Drug Discovery, and Nabil Uddin, Pharm.D., as Vice President of Method and Small business Growth.
“We are delighted to be rising the Rheos management staff with the addition of these two attained marketplace leaders, deepening our expertise in essential regions of our science and organization to help our potential development,” reported Barbara Fox, Ph.D., Chief Government Officer of Rheos. “Katerina delivers considerable working experience in tiny molecule drug discovery and a thriving track file for advancing drug candidates to the clinic in a selection of therapeutic regions. Nabil’s various know-how throughout system, functions and company enhancement features in the biopharma sector and his verified skills in creating techniques in new marketplace areas will be a must have as Rheos evolves our pipeline options.”
Katerina Leftheris, Ph.D., Senior Vice President, Drug Discovery
“I search ahead to implementing my expertise to assistance advance Rheos’s pipeline to create precision medicines for autoimmune and inflammatory conditions,” stated Dr. Leftheris. “I see remarkable prospective for the company’s groundbreaking approach to concentrating on basic metabolic underpinnings of immune program dysfunction although also determining the molecular signatures for affected individual subsets. It is remarkable to be part of a new drug enhancement paradigm at Rheos to deal with the heterogeneity of immune-mediated illnesses and get on the wide unmet needs of individuals.”
Katerina Leftheris, Ph.D., delivers over 20 many years of small molecule drug discovery and advancement encounter, like various drug assets in Stage 1, 2 and 3 concentrating on immune modulation, fibrosis, oncology and immuno-oncology indications. Through her vocation, she has led teams that highly developed a lot more than 15 small molecule drug compounds into clinical improvement spanning many molecular targets. Most lately, she was Vice President of Chemistry at Pliant Therapeutics, a biotech organization concentrated on novel treatment plans for fibrotic conditions. Katerina assisted construct Pliant’s drug discovery capabilities which led to two medications in the clinic (1 partnered with Novartis) for the cure of idiopathic pulmonary fibrosis (IPF), main sclerosing cholangitis (PSC) and NASH with a third compound focused on immuno-oncology in early enhancement. Earlier, Katerina was Senior Director in Discovery for Celgene, San Diego, in which she developed and led groups in advancing five novel scientific candidates in immunology and oncology. Before in her job, she served in R&D roles at Vitae Pharmaceuticals and at Bristol-Myers Squibb’s Discovery Oncology and Immunology Chemistry team. Katerina was elected to the Countrywide Council of the American Chemical Culture and she has authored around 135 publications and issued patents. She gained a B.A. in chemistry/biochemistry from Smith College or university, a Ph.D. in organic chemistry from the University of California, San Diego and completed postdoctoral research at the College of Pennsylvania.
Nabil Uddin, Pharm.D., Vice President, Strategy & Enterprise Enhancement
“This is an enjoyable time to sign up for Rheos as the company can make development with its precision medicine tactic to autoimmune and inflammatory conditions, moves its very first drug candidate towards the clinic, and further more evolves its pipeline,” stated Dr. Uddin. “I am eager to leverage my working experience to help the company’s growth, and I glimpse forward to doing work with the talented Rheos workforce to obtain our shared plans and mission to make a variation in the life of sufferers across lots of conditions.”
Nabil Uddin, Pharm.D., joins Rheos with in excess of 15 years of knowledge throughout strategic and operational functions, together with software and alliance administration, portfolio preparing, company method and business enhancement. Most a short while ago, he served as Vice President, Corporate Improvement at Concert Prescription drugs where he was dependable for company technique, enterprise advancement, program administration and professional organizing. Nabil joined Concert to present strategic and operational leadership for a plan in cystic fibrosis that was eventually acquired by Vertex Pharmaceuticals. Prior to Live performance, Nabil worked at Seaside Therapeutics, a organization concentrated on neurodevelopmental problems these as Fragile X Syndrome and autism spectrum ailments. Earlier in his job he served as a marketing consultant delivering strategic scheduling and method administration providers. Nabil gained a B.Sc. in Biology from McMaster College, a Pharm.D. from the Massachusetts University of Pharmacy and accomplished a postdoctoral fellowship at the University of North Carolina at Chapel Hill.
About Rheos Medications
Rheos Medicines is a biopharmaceutical enterprise acquiring precision medicines to take care of autoimmune and inflammatory disorders by identifying and concentrating on the molecular properties and affected individual subsets for these sophisticated disorders. Using our proprietary MetPM™ platform, the Rheos staff integrates an unmatched knowledge foundation of immunometabolism networks based mostly on bioinformatic integration of genetic, transcriptomic, epigenomic and metabolomic datasets, like from patient data and samples. We have created a pipeline of novel, differentiated drug systems to tackle autoimmune and inflammatory ailments by targeting basic underpinnings of immune procedure dysfunction even though, at the similar time, determining the molecular signatures for affected person stratification and collection. Rheos has assembled primary researchers whose discoveries opened the subject of immunometabolism, clinicians with a deep knowledge of immune-mediated disorders, and an seasoned biotech leadership group. Rheos was launched by 3rd Rock Ventures and is positioned in Cambridge, MA. For extra info, please check out www.rheosrx.com/. We invite you to comply with us on LinkedIn and @Rheosrx.
Check out resource edition on businesswire.com: https://www.businesswire.com/information/house/20220414005168/en/
Contacts
Media:
Kathryn Morris, The Yates Network LLC
914-204-6412
[email protected]
Buyers:
Hannah Deresiewicz, Stern Trader Relations, Inc.
212-362-1200
[email protected]